Roth MKM lowered the firm’s price target on Assertio Holdings to $3.50 from $7 and keeps a Buy rating on the shares. The company’s Q3 results were “fundamentally below expectations”, with Indocin forecasts lowered due to competition from compounders and Rolvedon forecasts lowered due to inflated base and less reaction to J-Code, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASRT:
- Assertio Holdings reports Q3 EPS 1c, consensus 11c
- Assertio Reports Third Quarter 2023 Financial Results
- Assertio Therapeutics (ASRT) Q3 Earnings Cheat Sheet
- Assertio Holdings price target lowered to $4 from $6 at BWS Financial
- Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023